Celltrion to strengthen biosimilar lineup in Australia

Celltrion, a leading Korean biopharmaceutical company, said Thursday it will strengthen its biosimilar lineup in Australia to meet rising demand in the core Oceania market. Celltrion recently launched two biosimilars in Australia: Omlyclo, a treatment for allergic diseases, and Steqeyma, treatment for autoimmune diseases, the company said in a press release. The company plans to introduce two more biosimilars in Australia next year — Avtozma for autoimmune disease treatment and Stoboclo-Osenvelt for osteoporosis treatment. "The Australian biosimilar market is expected to expand further as local authorities provide various support measures, including a simplified approval process, to encourage adoption of biosimilars," a company spokesperson said. Previously, six Celltrion biosimilars were available in the Australian market: Remsima (sold locally as Inflectra), Remsima SC, Yuflyma, Herzuma, Truxima and Vegzelma. In the January-June period, the company posted a net profit of 171.6 billion won ($123 million) on sales of 961.5 billion won. Celltrion aims to achieve 5 trillion won in annual sWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times